Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13011460 | 0.91 | OPRK1 (0.55) | CNR1ALDH1A1SCARB1NPY5R | |
| SCHEMBL13011314 | 0.86 | PTGER4 (0.59) | CNR1ALDH1A1NPY5R | |
| SCHEMBL13011809 | 0.80 | CNR1 (0.48) | CNR1ATMNPY5R | |
| SCHEMBL13011462 | 0.80 | SCARB1 (0.52) | ALDH1A1SCARB1 | |
| SCHEMBL16880308 | 0.79 | CNR1 (0.60) | CNR1 | |
| SCHEMBL3932512 | 0.79 | CNR2 (0.59) | ALDH1A1SCARB1 | |
| SCHEMBL18028054 | 0.78 | TSHR (0.64) | CNR1ALDH1A1ATM | |
| SCHEMBL13011120 | 0.77 | CNR2 (0.52) | CNR1ALDH1A1SCARB1 | |
| SCHEMBL13011578 | 0.77 | TSHR (0.56) | ALDH1A1SCARB1 | |
| SCHEMBL13011142 | 0.77 | SCARB1 (0.52) | ALDH1A1SCARB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | CNR1 776/4885ALDH1A1 2104/4885ATM 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.